Protara Therapeutics

Protara Therapeutics
(NASDAQ: TARA)
New York, NY, USA
Year of Investment: 2014

IPO in October, 2014
Merger transaction between Proteon and ArTara in January, 2020

Protara Therapeutics(NASDAQ: TARA)
New York, NY, USA
Year of Investment: 2014

IPO in October, 2014
Merger transaction between Proteon and ArTara in January, 2020

Protara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. Protara's current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company's lead program, TARA-002, is being developed for the treatment of lymphatic malformations. Protara's second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of IFALD
http://protaratx.com/

Protara Latest News
12.10.2021
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
13.09.2021
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition

Read more news

← Previous

Protagonist Therapeutics

Allena Pharmaceuticals

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally

Back to Portfolio